T. Rowe Price Associates’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-75,259
| Closed | -$2.96M | – | 2952 |
|
|
2023
Q2 | $2.96M | Sell |
75,259
-6,737,387
| -99% | -$238M | ﹤0.01% | 1345 |
|
|
2023
Q1 | $166M | Buy |
6,812,646
+1,968,987
| +41% | +$43.1M | 0.02% | 413 |
|
|
2022
Q4 | $104M | Buy |
4,843,659
+1,397,305
| +41% | +$29.8M | 0.02% | 486 |
|
|
2022
Q3 | $61.8M | Buy |
3,446,354
+56,214
| +2% | +$738K | 0.01% | 593 |
|
|
2022
Q2 | $32.6M | Sell |
3,390,140
-1,220,136
| -26% | -$15.3M | ﹤0.01% | 1017 |
|
|
2022
Q1 | $77.6M | Sell |
4,610,276
-436,011
| -9% | -$6.44M | 0.01% | 813 |
|
|
2021
Q4 | $84.4M | Buy |
5,046,287
+66,889
| +1% | +$1.1M | 0.01% | 820 |
|
|
2021
Q3 | $80.9M | Buy |
4,979,398
+2,926,658
| +143% | +$31.9M | 0.01% | 837 |
|
|
2021
Q2 | $13M | Sell |
2,052,740
-110,452
| -5% | -$713K | ﹤0.01% | 1384 |
|
|
2021
Q1 | $13.4M | Buy |
2,163,192
+9,520
| +0.4% | +$57.8K | ﹤0.01% | 1349 |
|
|
2020
Q4 | $14.9M | Sell |
2,153,672
-23,552
| -1% | -$151K | ﹤0.01% | 1287 |
|
|
2020
Q3 | $12.3M | Sell |
2,177,224
-652,127
| -23% | -$3.11M | ﹤0.01% | 1253 |
|
|
2020
Q2 | $14.4M | Buy |
+2,829,351
| New | +$11.8M | ﹤0.01% | 1226 |
|
|
2017
Q1 | – | Sell |
-578,795
| Closed | -$2.8M | – | 2602 |
|
|
2016
Q4 | $2.8M | Sell |
578,795
-1,476,967
| -72% | -$43.8M | ﹤0.01% | 1498 |
|
|
2016
Q3 | $94.8M | Buy |
2,055,762
+288,200
| +16% | +$16.3M | 0.02% | 591 |
|
|
2016
Q2 | $90.2M | Sell |
1,767,562
-665
| -0% | -$33K | 0.02% | 600 |
|
|
2016
Q1 | $74.7M | Buy |
1,768,227
+128,300
| +8% | +$6.54M | 0.02% | 640 |
|
|
2015
Q4 | $129M | Sell |
1,639,927
-296,887
| -15% | -$17.2M | 0.03% | 493 |
|
|
2015
Q3 | $78.5M | Sell |
1,936,814
-74,594
| -4% | -$3.95M | 0.02% | 637 |
|
|
2015
Q2 | $105M | Buy |
2,011,408
+610,442
| +44% | +$30.4M | 0.02% | 590 |
|
|
2015
Q1 | $65.2M | Buy |
1,400,966
+30,924
| +2% | +$1.61M | 0.01% | 745 |
|
|
2014
Q4 | $61.5M | Buy |
1,370,042
+1,668
| +0.1% | +$70.1K | 0.01% | 775 |
|
|
2014
Q3 | $53.3M | Buy |
1,368,374
+175,827
| +15% | +$6.9M | 0.01% | 815 |
|
|
2014
Q2 | $50.5M | Buy |
1,192,547
+196,724
| +20% | +$7.22M | 0.01% | 867 |
|
|
2014
Q1 | $35.6M | Buy |
995,823
+166,700
| +20% | +$5.62M | 0.01% | 961 |
|
|
2013
Q4 | $26.8M | Buy |
+829,123
| New | +$24.6M | 0.01% | 1013 |
|
T. Rowe Price Associates's ISEE Position: Q3 2023 in Review
T. Rowe Price Associates sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 75,259 shares — an estimated $2.96M sold.
T. Rowe Price Associates first reported a position in ISEE in Q4 2013 and held it in 26 quarters. The position peaked at $166M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- T. Rowe Price Associates reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- T. Rowe Price Associates sold 75,259 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $2.96M.
- T. Rowe Price Associates first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 26 quarters.
- T. Rowe Price Associates's IVERIC bio, Inc. Common Stock position peaked at $166M in Q1 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.